Kilovoltage intratreatment monitoring (KIM) is a novel real-time localization modality where the tumor position is continuously measured during intensity modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) by a kilovoltage (kV) x-ray imager. Adding kV imaging during therapy adds radiation dose. The additional effective dose is quantified for prostate radiotherapy and compared to dose from other localization modalities. The software PCXMC 2.0 was used to calculate the effective dose delivered to a phantom as a function of imager angle and field size for a Varian On-Board Imager. The average angular effective dose was calculated for a field size of 6 cm × 6 cm. The average angular effective dose was used in calculations for different treatment scenarios. Treatment scenarios considered were treatment type and fractionation. For all treatment scenarios, (i.e. conventionally fractionated and stereotactic body radiotherapy (SBRT), IMRT and IMAT), the total KIM dose at 1 Hz ranged from 2-10 mSv. This imaging dose is less than the Navotek radioactive implant dose (64 mSv) and a standard SBRT cone beam computed tomography pretreatment scan dose (22 mSv) over an entire treatment regime. KIM delivers an acceptably low effective dose for daily use as a real-time image-guidance method for prostate radiotherapy.
Kilovoltage intratreatment monitoring (KIM) is a novel real-time localization modality where the tumor position is continuously measured during intensity modupan class="Gene">lated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) by a kilovoltage (kV) x-ray imager. Adding kV imaging during therapy adds radiation dose. The additional effective dose is quantified for prostate radiotherapy and compared to dose from other localization modalities. The software PCXMC 2.0 was used to calculate the effective dose delivered to a phantom as a function of imager angle and field size for a Varian On-Board Imager. The average angular effective dose was calculated for a field size of 6 cm × 6 cm. The average angular effective dose was used in calculations for different treatment scenarios. Treatment scenarios considered were treatment type and fractionation. For all treatment scenarios, (i.e. conventionally fractionated and stereotactic body radiotherapy (SBRT), IMRT and IMAT), the total KIM dose at 1 Hz ranged from 2-10 mSv. This imaging dose is less than the Navotek radioactive implant dose (64 mSv) and a standard SBRT cone beam computed tomography pretreatment scan dose (22 mSv) over an entire treatment regime. KIM delivers an acceptably low effective dose for daily use as a real-time image-guidance method for prostate radiotherapy.
Authors: Martin J Murphy; James Balter; Stephen Balter; Jose A BenComo; Indra J Das; Steve B Jiang; C M Ma; Gustavo H Olivera; Raymond F Rodebaugh; Kenneth J Ruchala; Hiroki Shirato; Fang-Fang Yin Journal: Med Phys Date: 2007-10 Impact factor: 4.071
Authors: Berit L Madsen; R Alex Hsi; Huong T Pham; Jack F Fowler; Laura Esagui; John Corman Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-15 Impact factor: 7.038
Authors: Per Rugaard Poulsen; Byungchul Cho; Dan Ruan; Amit Sawant; Paul J Keall Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-03 Impact factor: 7.038
Authors: Christopher R King; James D Brooks; Harcharan Gill; Todd Pawlicki; Cristian Cotrutz; Joseph C Presti Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-26 Impact factor: 7.038
Authors: Christoph Bert; Christian Graeff; Marco Riboldi; Simeon Nill; Guido Baroni; Antje-Christin Knopf Journal: Technol Cancer Res Treat Date: 2013-12-17
Authors: Kimberley Legge; Peter B Greer; Paul J Keall; Jeremy T Booth; Sankar Arumugam; Trevor Moodie; Doan T Nguyen; Jarad Martin; Daryl John O'Connor; Joerg Lehmann Journal: J Appl Clin Med Phys Date: 2017-08-02 Impact factor: 2.102